Subscribe To

Price Alert Latest News Economic Calendar News

OCTHF / Oxford Cannabinoid Technologies upbeat ahead of pivotal trial

Oxford Cannabinoid Technologies' interim chief executive said the company has made good progress over the past six months and had 'laid the groundwork for an exciting 2023'. "This was a busy and pivotal period for the company and we are delighted with the progress,” said Clarissa Sowemimo-Coker. Read More

Demo Live Account See Partner Details

Content Topics

Oxford

Cannabinoid

Technologies

Upbeat

Ahead

Pivotal

Trial

Stock

OCTHF

Posted: Jan 23 2023, 04:04

Author Name: Proactive Investors

OCTHF News

By Proactive Investors
October 24, 2023

Oxford Cannabinoid Technologies delighted with phase 1 outcome for pain drug

Clarissa Sowemimo-Coker, CEO of Oxford Cannabinoid Technologies Holdings, discusses with Proactive's Thomas Warner the successful completion of a phas

By Proactive Investors
October 10, 2023

Oxford Cannabinoid Technologies shares jumo 6% on successful completion of phase I study

Shares in Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) rose 6% following the successful completion of the phase I study for its

By Proactive Investors
October 10, 2023

Oxford Cannabinoid readies for next stage as it safely navigates phase I stduy

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTC:OCTHF) hailed as a 'major milestone' the successful completion of dosing for all cohorts

By Proactive Investors
September 25, 2023

Oxford Cannabinoid Technologies completes final dose in phase I trial of lead asset

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) has successfully administered the final dose of its lead drug candidate, OCT46120

By Proactive Investors
August 31, 2023

Oxford Cannabinoid Technologies hails defining year as clinical trials remain on track

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) hailed a “defining year” for the progress of its leading drug candidates and

By Proactive Investors
July 27, 2023

Oxford Cannabinoid Technologies takes pain drug into phase I; appoints leading pain expert

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) said it has commenced its phase I clinical trial for the lead drug candidate, OC

By Proactive Investors
July 17, 2023

Oxford Cannabinoid jumps as firm hints cheaper cancer treatments

Shares in Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) rose 10% on Monday as the pharmaceutical company formally announced its

By Proactive Investors
July 17, 2023

Oxford Cannabinoid expands into oncology with potential new cannabinoid-based treatment

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF), a pharmaceutical company specialising in prescription cannabinoid medicines, is

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Subscribe To

Live Trading Account

Open live account in few minutes with just 10$

OCTHF / Oxford Cannabinoid Technologies upbeat ahead of pivotal trial

Oxford

Cannabinoid

Technologies

Upbeat

Ahead

Pivotal

Trial

Stock

OCTHF

OCTHF News

Oxford Cannabinoid Technologies delighted with phase 1 outcome for pain drug

Oxford Cannabinoid Technologies shares jumo 6% on successful completion of phase I study

Oxford Cannabinoid readies for next stage as it safely navigates phase I stduy

Oxford Cannabinoid Technologies completes final dose in phase I trial of lead asset

Oxford Cannabinoid Technologies hails defining year as clinical trials remain on track

Oxford Cannabinoid Technologies takes pain drug into phase I; appoints leading pain expert

Oxford Cannabinoid jumps as firm hints cheaper cancer treatments

Oxford Cannabinoid expands into oncology with potential new cannabinoid-based treatment